Cuizhi Geng

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 372 citations

Capecitabine Versus Lapatinib, Breast Oncology, Medicine +8

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Zefei Jiang, Wei Li, Xichun Hu et al. · The Lancet Oncology · 2019 · 261 citations

Breast Oncology, Medicine, Pharmacology +8

Biomarkers for EMT and MET in breast cancer: An update

Fei Liu, Lina Gu, Baoen Shan et al. · Oncology Letters · 2016 · 127 citations · Full text

Epithelial-mesenchymal Transition, Emt Markers, Emt Biomarkers +15

Circular RNA ciRS-7 Maintains Metastatic Phenotypes as a ceRNA of miR-1299 to Target MMPs

Meixiang Sang, Lingjiao Meng, Sihua Liu et al. · Molecular Cancer Research · 2018 · 100 citations